The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Allakos Inc(NASDAQ:ALLK)


Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic es...
Website: http://www.allakos.com
Founded: 2012
Full Time Employees: 114
CEO: Robert D. Alexander Ph.D.
Sector: Healthcare
Industry: Biotechnology
Allakos Days Payable Outstanding ttm (DPO)
Allakos Op Cashflow Per Share ttm
Allakos Free Cashflow Per Share ttm
Allakos Cash Per Share ttm
Allakos (GAAP) P/E ratio ttm
Allakos P/B ratio ttm
No extra charts and metrics for this ticker.